Post Traumatic Stress Disorder Trials Should Use Fixed Dose, Committee Says
Executive Summary
Sponsors seeking a post traumatic stress disorder indication should conduct fixed-dose studies, FDA's Psychopharmacologic Drugs Advisory Committee advised during its Oct. 8 review of Pfizer's Zoloft.
You may also be interested in...
Zoloft PTSD Claim Clears FDA Cmte.; More Studies In Men Sought
Additional trials of Pfizer's Zoloft (sertraline) in post-traumatic stress disorder should focus on the drug's treatment benefit in men, FDA's Psychopharmacologic Drugs Advisory Committee said Oct. 8. The committee recommended approval of the product for PTSD.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials